These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 39177282)

  • 1. Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis.
    Ek T; Ibrahim RR; Vogt H; Georgantzi K; Träger C; Gaarder J; Djos A; Rahmqvist I; Mellström E; Pujol-Calderón F; Vannas C; Hansson L; Fagman H; Treis D; Fransson S; Österlund T; Chuang TP; Verhoeven BM; Ståhlberg A; Palmer RH; Hallberg B; Martinsson T; Kogner P; Dalin M
    Cancer Res Commun; 2024 Sep; 4(9):2553-2564. PubMed ID: 39177282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed
    Liu T; Merguerian MD; Rowe SP; Pratilas CA; Chen AR; Ladle BH
    Cold Spring Harb Mol Case Stud; 2021 Aug; 7(4):. PubMed ID: 34210658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.
    Berko ER; Witek GM; Matkar S; Petrova ZO; Wu MA; Smith CM; Daniels A; Kalna J; Kennedy A; Gostuski I; Casey C; Krytska K; Gerelus M; Pavlick D; Ghazarian S; Park JR; Marachelian A; Maris JM; Goldsmith KC; Radhakrishnan R; Lemmon MA; Mossé YP
    Nat Commun; 2023 May; 14(1):2601. PubMed ID: 37147298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving ALK-Targeted Therapy.
    Bobin C; Iddir Y; Butterworth C; Masliah-Planchon J; Saint-Charles A; Bellini A; Bhalshankar J; Pierron G; Combaret V; Attignon V; André N; Corradini N; Dumont B; Mansuy L; Khanfar C; Klein S; Briandet C; Plantaz D; Millot F; Thouvenin S; Aerts I; Ndounga-Diakou LA; Laghouati S; Abbou S; Jehanno N; Tissot H; Renault S; Baulande S; Raynal V; Bozec L; Bieche I; Delattre O; Berlanga P; Schleiermacher G
    Clin Cancer Res; 2024 Aug; 30(15):3316-3328. PubMed ID: 38787533
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Shaw AT; Solomon BJ; Besse B; Bauer TM; Lin CC; Soo RA; Riely GJ; Ou SI; Clancy JS; Li S; Abbattista A; Thurm H; Satouchi M; Camidge DR; Kao S; Chiari R; Gadgeel SM; Felip E; Martini JF
    J Clin Oncol; 2019 Jun; 37(16):1370-1379. PubMed ID: 30892989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.
    Goldsmith KC; Park JR; Kayser K; Malvar J; Chi YY; Groshen SG; Villablanca JG; Krytska K; Lai LM; Acharya PT; Goodarzian F; Pawel B; Shimada H; Ghazarian S; States L; Marshall L; Chesler L; Granger M; Desai AV; Mody R; Morgenstern DA; Shusterman S; Macy ME; Pinto N; Schleiermacher G; Vo K; Thurm HC; Chen J; Liyanage M; Peltz G; Matthay KK; Berko ER; Maris JM; Marachelian A; Mossé YP
    Nat Med; 2023 May; 29(5):1092-1102. PubMed ID: 37012551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
    Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
    Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic monitoring of circulating tumor DNA to analyze genetic characteristics and resistance profile of lorlatinib in ALK positive previously treated NSCLC.
    Ma X; Zhang K; Xu J; Gao H; Yang S; Qin H; Wang H; Gao F; Liu X
    Thorac Cancer; 2023 Jul; 14(20):1980-1990. PubMed ID: 37265111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metastatic Non-Myofibroblastic Sarcoma Harbouring EML4-ALK Fusion-Dramatic Response to ALK Tyrosine Kinase Inhibitors and Development of Resistance Mutations.
    Wilson I; Qiu M; Itchins M; Wang B; Huang ML; Grimison P
    Cancer Rep (Hoboken); 2024 Aug; 7(8):e2164. PubMed ID: 39188081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific Relapse.
    Dagogo-Jack I; Oxnard GR; Evangelist M; Digumarthy SR; Lin JJ; Gainor JF; Murphy JF; Rabin MS; Heist RS; Muzikansky A; Shaw AT
    JCO Precis Oncol; 2022 May; 6():e2100522. PubMed ID: 35584349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SHP2 Inhibition with TNO155 Increases Efficacy and Overcomes Resistance of ALK Inhibitors in Neuroblastoma.
    Valencia-Sama I; Kee L; Christopher G; Ohh M; Layeghifard M; Shlien A; Hayes MN; Irwin MS
    Cancer Res Commun; 2023 Dec; 3(12):2608-2622. PubMed ID: 38032104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma.
    Suk Y; Singh SK
    Cell Rep Med; 2023 Jun; 4(6):101071. PubMed ID: 37343514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN.
    Guan J; Tucker ER; Wan H; Chand D; Danielson LS; Ruuth K; El Wakil A; Witek B; Jamin Y; Umapathy G; Robinson SP; Johnson TW; Smeal T; Martinsson T; Chesler L; Palmer RH; Hallberg B
    Dis Model Mech; 2016 Sep; 9(9):941-52. PubMed ID: 27483357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models.
    Tucker ER; Jiménez I; Chen L; Bellini A; Gorrini C; Calton E; Gao Q; Che H; Poon E; Jamin Y; Martins Da Costa B; Barker K; Shrestha S; Hutchinson JC; Dhariwal S; Goodman A; Del Nery E; Gestraud P; Bhalshankar J; Iddir Y; Saberi-Ansari E; Saint-Charles A; Geoerger B; Marques Da Costa ME; Pierre-Eugène C; Janoueix-Lerosey I; Decaudin D; Nemati F; Carcaboso AM; Surdez D; Delattre O; George SL; Chesler L; Tweddle DA; Schleiermacher G
    Clin Cancer Res; 2023 Apr; 29(7):1317-1331. PubMed ID: 36602782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC.
    Soo RA; Martini JF; van der Wekken AJ; Teraoka S; Ferrara R; Shaw AT; Shepard D; Calella AM; Polli A; Toffalorio F; Tomasini P; Chiu CH; Kowalski DM; Kim HR; Solomon BJ
    J Thorac Oncol; 2023 Nov; 18(11):1568-1580. PubMed ID: 37295609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.
    Okada K; Araki M; Sakashita T; Ma B; Kanada R; Yanagitani N; Horiike A; Koike S; Oh-Hara T; Watanabe K; Tamai K; Maemondo M; Nishio M; Ishikawa T; Okuno Y; Fujita N; Katayama R
    EBioMedicine; 2019 Mar; 41():105-119. PubMed ID: 30662002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report.
    Hu J; Zhang B; Yao F; Fu Y; Chen D; Li D; Du N; Lizaso A; Song J; Zhang L; Li X
    Ther Adv Respir Dis; 2020; 14():1753466620935770. PubMed ID: 32600123
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations.
    Bearz A; Martini JF; Jassem J; Kim SW; Chang GC; Shaw AT; Shepard DA; Dall'O' E; Polli A; Thurm H; Zalcman G; Garcia Campelo MR; Penkov K; Hayashi H; Solomon BJ
    J Thorac Oncol; 2023 Nov; 18(11):1581-1593. PubMed ID: 37541389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound
    Yoda S; Lin JJ; Lawrence MS; Burke BJ; Friboulet L; Langenbucher A; Dardaei L; Prutisto-Chang K; Dagogo-Jack I; Timofeevski S; Hubbeling H; Gainor JF; Ferris LA; Riley AK; Kattermann KE; Timonina D; Heist RS; Iafrate AJ; Benes CH; Lennerz JK; Mino-Kenudson M; Engelman JA; Johnson TW; Hata AN; Shaw AT
    Cancer Discov; 2018 Jun; 8(6):714-729. PubMed ID: 29650534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dissecting the role of ALK double mutations in drug resistance to lorlatinib with in-depth theoretical modeling and analysis.
    Zhang X; Tong J; Wang T; Wang T; Xu L; Wang Z; Hou T; Pan P
    Comput Biol Med; 2024 Feb; 169():107815. PubMed ID: 38128254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.